“The Heart Will Go On”: Recent Updates in the Treatment of HFpEF

<p>Divya A. Khandekar, Pharm.D., M.S., compares and contrasts the etiologies of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), discusses primary literature examining current treatment options for HFpEF and identifies the role of SGLT2 inhibitors in the treatment of HFpEF. </p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>